ESMO Media Releases

The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the TAT (Targeted Anticancer Therapies) International Congress 2019

The TAT 2019 Honorary Award for cancer drug development has been given to Dr Geoffrey Shapiro for his leadership in developmental therapeutics, particularly in solid tumours

Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.

First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.

New technologies in immuno-oncology that are set to benefit many more patients with cancer are being showcased at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland

Researchers predict that death rates from cancer will fall in 2018 in Australasian countries and in Russia. However, a greater proportion of the population will die in Russia from the disease than in any of the other countries, mainly because of the large numbers of men who still smoke.

ESMO is pleased to announce the ESMO Immuno-Oncology 2018 Congress, a dedicated platform in Europe to keep professionals up to date with the most recent and significant developments in this rapidly evolving field.

Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients – challenges which are best addressed through collaboration in international networks.

Misconceptions about the use of strong opioids showed to undermine optimal pain control among Asian cancer patients undergoing chemotherapy and radiotherapy according to a cross-sectional survey conducted at the Sarawak General Hospital in Malaysia.

The European Society for Medical Oncology (ESMO) has selected Prof. Cornelis Melief to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer.

The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the third ESMO Asia 2018 Congress. 

Patients with HPV-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy